Fund Management

Dr. Markus Goebel

is a Managing Director in Basel, Switzerland.

Prior to joining Novartis Venture Fund, he worked as head Novartis Pharmaceutical Corporate M&A and Head Nervous System Business Development & Licensing. An MD by training and certified, amongst others, in hematology/oncology he worked for Farmitalia Germany and later held several positions in R&D, Marketing and Strategy at Roche headquarters before joining Novartis. Markus received an MD and a PhD from the Ludwig Maximilian’s University in Munich and an MBA from Henley. Markus serves on the boards of eFFECTOR, Ra Pharmaceuticals and Trellis RSV Holdings, Inc.

Exits: Acorda Therapeutics, Inc. (NASDAQ: ACOR), EraGen Biosciences, Inc. (Acquired by Luminex Corporation)FoldRx Pharmaceuticals, Inc. (Acquired by Pfizer)Intellikine, Inc. (Acquired by Takeda)LigoCyte Pharmaceuticals, Inc. (Acquired by Takeda)Sirtris Pharmaceuticals, Inc. (Acquired by GlaxoSmithKline), Xenoport, Inc. (NASDAQ: XNPT).

Portfolio Companies

eFFECTOR Therapeutics, Inc. (Board Seat)

Ra Pharmaceuticals, Inc. (Board Seat)

Trellis RSV Holdings, Inc. (Board Seat)